1,350
Views
7
CrossRef citations to date
0
Altmetric
Research Article

A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231

, , , , , , , & show all
Pages 1811-1817 | Received 19 Sep 2017, Accepted 14 Nov 2017, Published online: 24 Nov 2017

References

  • Andresen TL, Jensen SS, Jørgensen K. (2005). Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97.
  • Banga AK. (2015). Therapeutic peptides and proteins: formulation, processing, and delivery systems. Boca Raton: CRC press.
  • Bruno BJ, Miller GD, Lim CS. (2013). Basics and recent advances in peptide and protein drug delivery.
  • Ding J, Chua PJ, Bay BH, et al. (2014). Scorpion venoms as a potential source of novel cancer therapeutic compounds. Exp Biol Med (Maywood) 239:387–93.
  • Du AW, Stenzel MH. (2014). Drug carriers for the delivery of therapeutic peptides. Biomacromolecules 15:1097–114.
  • Ezan E. (2013). Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 65:1065–73.
  • Gu Y, Liu S-L, Ju W-Z, et al. (2013). Analgesic-antitumor peptide induces apoptosis and inhibits the proliferation of SW480 human colon cancer cells. Oncol Lett 5:483–8.
  • Guo G, Cui Y, Chen H, et al. (2016). Analgesic-antitumor peptide inhibits the migration and invasion of HepG2 cells by an upregulated VGSC β1 subunit. Tumour Biol 37:3033–41.
  • Hall WA, Vallera DA. (2006). Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus 20:E23.
  • Hansen L, Larsen EKU, Nielsen EH, et al. (2013). Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. Nanoscale 5:8192–201.
  • Holst-Hansen C, Johannessen B, Hoyer-Hansen G, et al. (1996). Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14:297–307.
  • Kovalainen M, Mönkäre J, Riikonen J, et al. (2015). Novel delivery systems for improving the clinical use of peptides. Pharmacol Rev 67:541–61.
  • Li R, Zheng K, Hu P, et al. (2014). A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics 4:642.
  • Mcmahon BJ, Kwaan HC. (2015). Components of the plasminogen-plasmin system as biologic markers for cancer. Adv Exp Med Biol 867:145–56.
  • Montuori N, Ragno P. (2014). Role of uPA/uPAR in the modulation of angiogenesis. Chem Immunol Allergy 99:105–22.
  • O’halloran TV, Ahn R, Hankins P, et al. (2013). The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics 3:496.
  • Ortiz E, Gurrola GB, Schwartz EF, et al. (2015). Scorpion venom components as potential candidates for drug development. Toxicon 93:125–35.
  • Otvos L, Jr, Wade JD. (2014). Current challenges in peptide-based drug discovery. Front Chem 2:
  • Parkin DM. (2001). Global cancer statistics in the year 2000. Lancet Oncol 2:533–43.
  • Provenzano AE, Posteri R, Giansanti F, et al. (2016). Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera. Microb Cell Fact 15:194.
  • Roy DM, Walsh LA. (2014). Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer 6:81.
  • Shao J, Zhang R, Ge X, et al. (2007). Analgesic peptides in Buthus martensii Karsch: a traditional Chinese animal medicine. Asian J Tradit Med 2:45–50.
  • Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
  • Su M, Chang W, Zhang K, et al. (2016). Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris. Oncol Rep 35:1179–85.
  • Sun Q, Xu Q, Dong X, et al. (2008). A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. Int J Cancer 123:942–50.
  • Takei Y, Mizukami H, Saga Y, et al. (2005). Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro. Int J Cancer 113:54–8.
  • Todhunter DA, Hall WA, Rustamzadeh E, et al. (2004). A bispecific immunotoxin (DTAT13) targeting human IL‐13 receptor (IL‐13R) and urokinase‐type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 17:157–64.
  • Torchilin VP, Lukyanov AN. (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259–66.
  • Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. Ca Cancer J Clin 65:87–108.
  • Zhao Y, Cai X, Ye T, et al. (2011). Analgesic‐antitumor peptide inhibits proliferation and migration of SHG‐44 human malignant glioma cells. J Cell Biochem 112:2424–34.